Aim: The aim of this study was to verify the application of Overall Disability Sum Score (ODSS) for standardized clinical assessment of neurological involvement in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and its correlation with treatment response and longterm outcomes.
1
It is usually classified among the so-called antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitides. Nevertheless, ANCAs, usually directed against myeloperoxidase (MPO) on enzyme-linked immunosorbent assay, are found in approximately only 30% to 40% of cases. 2, 3 One of the most frequently involved systems in EGPA is the peripheral nervous system (PNS) (65%-76%), 2, [4] [5] [6] with patients predominantly developing mononeuritis multiplex rather than a distal asymmetric or symmetric polyneuropathy or a mononeuropathy of the cranial nerves. Neurological symptoms often dominate the clinical picture.
Despite treatment efficacy, disease relapse rates are, nevertheless, high, leading to cumulative long-term damage, and also neuropathy can cause chronic, residual functional deficits. 2, 5 Although deficits can disrupt day-to-day functioning and quality of life, few data have been reported on neurological disability, damage, and long-term outcome.
The Vasculitis Damage Index (VDI) is a validated score that quantifies damage from disease onset, irrespective of whether it was caused by disease or treatments. Easy to use and with good test-retest validity, the index has been approved by the Outcome Measures in Rheumatology group and the European League Against Rheumatism as a key outcome measure to record damage in ANCA-associated vasculitis clinical trials. 7, 8 The VDI nevertheless evaluates symptomatic neuropathy using only a single item in the neuropsychiatric section and makes no distinction between sensory and motor nerves. Nor is the severity of nerve involvement, patient disability, or therapeutic response taken into consideration.
The Inflammatory Neuropathy Cause and Treatment Overall Disability Sum Score (ODSS) measures functional limb disturbances, and it has been used as a primary end point for chronic inflammatory immune-mediated polyneuropathy clinical trials. 9 The disability scale is easily administrable and takes only a few minutes to be completed. It measures arm and leg disability and evaluates peripheral neurological damage and treatment response. 9 The aim of this study was to verify the application of ODSS in assessing neurological damage, long-term outcome, and improvement in EGPA patients.
PATIENTS AND METHODS

Patient Population
We retrospectively evaluated consecutive patients (inpatients and outpatients) affected by EGPA satisfying the American College of Rheumatology criteria 10 and the revised Chapel Hill Consensus Conference Nomenclature for vasculitides 11 who were referred to the Rheumatology Unit of the University of Padova, a tertiary vasculitis referral center, between 2010 and 2015. Basic demographic information, ANCA levels (indirect immunofluorescence or antigen-specific PR3 and MPO enzyme-linked immunosorbent assay), eosinophil count, clinical manifestations, relapses, treatments, and sequelae were routinely monitored at baseline and during the entire follow-up period. All data were entered into a computerized data bank.
The study was granted approval by the local ethics committee and was carried out in accordance with the principles of the Declaration of Helsinki. All potential participants were informed of the procedure, risks, and benefits of the study and were asked to sign informed consent forms.
Patient Assessment
Each patient was evaluated at the time of diagnosis and periodically, regardless of the presence of clinical signs of peripheral neuropathy, every 3 to 4 months during the first year and every 4 to 6 months for the second and ensuing years of the follow-up. At each examination, patients were assessed for disease activity using the Birmingham Vasculitis Activity Score (BVAS) version 3. 12 Remission was defined as a BVAS score of zero and absence of disease activity attributable to EGPA vasculitis manifestations for 3 or more consecutive months. 8 Relapses were defined as the recurrence, worsening, or newly developed clinical findings of EGPA, as defined by the BVAS. Eosinophil count increases without any other clinical EGPA manifestation and isolated asthma, sinusitis, or rhinitis exacerbations were registered but were not considered a relapse. 8 The number of relapses was calculated for each patient. Treatment failure was defined as the absence of clinical remission, occurrence of new vasculitis manifestations, or death while receiving treatment. 8 Vasculitis activity and damage were evaluated by 2 different rheumatologists (F.S. and R.P.) using the BVAS and VDI 12, 13 at each visit. The 2 assessors together also evaluated patients with PNS involvement at each examination using the ODSS assessment tool. Composed of arm and leg disability scales with a total score ranging from 0 ("no sign of disability") to 12 ("severely disabled"), the ODSS is formulated in a checklist format suitable for interviewing patients. Daily arm activities such as dressing the upper part of the body, washing and brushing hair, turning a key in a lock, using knife and fork, and doing or undoing buttons and zippers are all scored in 3 possible ways: "not affected," "affected but not prevented," and "prevented." These results are then translated into an arm grade ranging from 0 (normal arm ability) to 5 (severe signs and symptoms in both arms preventing all purposeful movement). The leg scale likewise highlights walking problems or the need of a walking aid or wheelchair. The results are translated into a leg grade ranging from 0 (walking is not affected) to 7 (restricted to wheelchair or bed most of the day, preventing all purposeful movements of the leg).
14 Clinical and electromyographic (EMG) criteria were used to distinguish between axonal mononeuritis multiplex and polyneuropathy. Axonal neuropathies were defined as a reduction or a loss of compound sensory nerve or compound muscle action potential amplitudes at nerve conduction studies, a normal or slightly reduced conduction velocity, and typical EMG changes with (a) pathological spontaneous activity in acute lesions and (b) signs of initial or complete reinnervation in the subacute and chronic phases. A bilateral diffuse length-dependent reduced/absent ankle reflexes and decreased superficial tactile sensation, evaluated with a wisp of cotton, were the criteria used to classify the patient as suffering from symmetrical polyneuropathy. Muscle weakness or atrophy was not necessary. In addition, at least 1 positive (tingling, pain or allodynia) or negative (numbness, hypesthesia) symptom needed to be present in the extremities. In mononeuritis multiplex, the electromyogram uncovered neuropathic changes and pathological spontaneous activity in the muscle innervated by the affected nerve and normal findings in the muscle innervated by the contiguous nerve. Weakness of the muscle that was supplied by the affected single nerves needed to be associated with numbness (loss of sensation) in the territory of the same nerve.
In these patients, the EMG assessment was conducted every 6 months for the first year and annually thereafter. A neurological relapse was defined as the onset or worsening of symptoms such as tingling, pain, allodynia, numbness, or weakness in 1 or more limbs documented by clinical and EMG evaluation.
Statistical Analysis
Data are expressed as means ± SD for continuous variables and the number (%) for categorical ones. Student t tests were used to compare the differences in the means for normally distributed variables and the Mann-Whitney U test for nonparametric variables. A χ 2 test or Fisher exact test was used to compare differences in proportions. A 2-tailed P ≤ 0.05 was considered statistically significant. Interobserver agreement was quantified using Cohen κ for 2 raters. Data were analyzed using GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA).
RESULTS
Seventy-one patients affected with EGPA were referred to our center between 2010 and 2015. Twenty-one patients were excluded because of lack of data regarding the disease onset or the follow-up, whereas 50 patients were considered eligible and were enrolled. Each patient was evaluated at the time of diagnosis and every 3 to 4 months for the first year and then every 4 to 6 months during a mean follow-up of 75 months (9-180 months). Interobserver agreement for ODSS scoring resulted in a κ of 0.96. Patients' demographic, clinical, and laboratory data are outlined in Table 1 . Pulmonary and ear, nose, and throat involvement was the main symptoms (94% and 76%, respectively), including asthma, pulmonary infiltrates, nasal polyposis, and chronic rhinitis. Peripheral neuropathy was found in 25 patients (50%). 
Clinical Features of Patients With Peripheral Neuropathy
No sex, race, or diagnostic delay differences were noted when the patients with and without neurological involvement were compared (Table 2 and Fig. 1 ). Age at onset of vasculitis was significantly higher in the patients with neuropathy (56.3 ± 13.4 years) compared with those without neurological involvement (44.4 ± 12.1 years) (P = 0.0009). Antineutrophil cytoplasmic antibody-MPO antibodies were significantly associated with neuropathy (48% vs. 16%) (P = 0.015), as well as the eosinophil blood count (6886 ± 5964/μL vs. 2485 ± 1839/μL) (P = 0.0007). Pulmonary and ear, nose, and throat involvement was again the main symptoms in both groups (100% and 68% in patients with neuropathy and 88% and 52% in those without, respectively); the difference was not significant. Patients with active neuropathy were more likely to have renal involvement (24% vs. 0%) (P = 0.022). There was no association between the presence or absence of neuropathy and the occurrence of other lifethreatening organ-related manifestations (cardiovascular or abdominal). Baseline disease activity was higher in patients with vasculitic neuropathy (mean BVAS version 3 score 14.2 ± 4.2) compared with those without peripheral neuropathy (mean BVAS version 3 score 8.5 ± 4.3) (P < 0.0001). The mean ODSS score at diagnosis was 4.2 ± 2.4, and there was no statistically significant difference between patients affected by mononeuritis multiplex or symmetric polyneuropathy. The patients were divided into 2 groups according to severity of neurological involvement determined by ODSS at baseline: patients with an ODSS value of 3 or less (n = 12 [48%]), who have symptoms or signs preventing at least 1 but not all functions listed in the score, and those with an ODSS value of greater than 3 (n = 13 [52%]), who have all functions listed in the score prevented almost in 1 limb (Table 3) . Those in the latter group had a higher ANCA-MPO positivity (69%) compared with those in the group with less severe neuropathy (25%, P = 0.027); there were no differences in age, diagnostic delay, and baseline BVAS values in the 2 patient groups.
Follow-up and Prognosis
All the patients were treated with corticosteroids and immunosuppressant drugs during active disease periods. Patients with neurological involvement were more likely to be treated with high doses of corticosteroids (1 g/d for 3 days then 1 mg/kg per day tapered slowly to reach 5-10 mg/d at 6 months) and intravenous pulse cyclophosphamide (60% vs. 4%) (P < 0.0001) ( Table 2) , which was administered in 6 monthly cycles at the dose of 750 mg/m 2 . Therapy was effective in normalizing eosinophilia (from mean value of 4863 ± 2393/μL to 756 ± 429/μL) within a short period and ANCA positivity (from 32% to 8% of patients) in 6 months. The BVAS was significantly lower at the last examination (2.4 ± 1.7) in the entire population with respect to the baseline value (14.2 ± 4.2) (P = 0.0001). Clinical and EMG evaluations during the study period showed both an improvement in motor deficits and a reduction in sensory ones. All the patients nevertheless developed chronic neuropathy (damage lasting >3 months as registered on the VDI) despite remission from active vasculitis, according to the BVAS. Furthermore, the electromyography persistently detected axonal nerve damage. Patients affected by neuropathy had significantly more systemic organ damage, resulting in a significantly higher VDI score (3.2 ± 1.4) at the last examination compared with those without neurological involvement (2.2 ± 1.3) (P = 0.01). All the patients, however, showed an improvement in disability and better functional ability according to both clinical evaluation and the ODSS score. An early response was observed within 6 months of treatment onset, resulting in a significant decrease in the ODSS from 4.2 ± 2.4 at baseline to 2.9 ± 1.5 (P = 0.0001) at 6 months. The ODSS values at 12 months (2.6 ± 1.5) and at the last examination (2.2 ± 1.2) showed only a progressively decreasing pattern. Patients with more severe neurological involvement and ODSS of greater than 3 at baseline (5 ± 1.7) showed a progressive improvement too, without reaching values less than 3 (3.1 ± 1.1) at the final examination (Fig. 2) . A significant positive correlation was found between the baseline ODSS value and the final VDI value (P = 0.0063), but no correlation was found between ODSS and BVAS. At the last examination, 46 patients (92%) had achieved clinical remission. During follow-up, 18 patients (20%) experienced 1 or more disease relapse, with the total number of relapses being 25, whereas 28 patients (56%) had chronic/ relapsing asthma and chronic rhinitis. Among the 25 patients with chronic neuropathy, neurological relapses were observed only in those (n = 7 [53.8%]) with an ODSS of greater than 3 (P = 0.027). None of the patients died.
DISCUSSION
Reported in up to 58% of patients affected by granulomatosis with polyangiitis and microscopic polyangiitis [15] [16] [17] and in up to 76% of patients with EGPA, peripheral nerve involvement is a common feature in patients with ANCA-associated vasculitis. The finding that 50% of the patients diagnosed as having EGPA studied here had an associated vasculitic neuropathy is in accordance with findings outlined by Comarmond et al., 2 who reported that 51.1% of 383 patients affected by EGPA participating in a large retrospective study had peripheral neuropathy. Often present at disease onset, 18, 19 it less frequently develops during relapses. 5 All the neurological manifestations found in our patients involved the peripheral nerves; there were no central nervous system findings. In line with previous studies 2,4 describing cranial nerve affection as a much less typical occurrence (in 3%-6.7% of patients), only 1 of our patients (2%) developed cranial nerve involvement (optic neuropathy). In accordance with other studies, mononeuritis multiplex was more common than symmetric polyneuropathy. 2, 4, 5, 20 No differences in race, sex, age, or organ involvement, except for a more frequent renal disease in the patients with neuropathy, were noted. Two distinct disease subtypes with different phenotypes and pathogenetic mechanisms have been proposed: ANCA-positive disease is characterized by small-vessel vasculitis with more frequently kidney and PNS involvement; ANCA-negative disease results from eosinophil-mediated damage and is associated with heart disease and fever. [21] [22] [23] The majority of our ANCA-positive patients had PNS involvement. However, a consistent number of patients affected by neuropathies were ANCA negative, as well as patients described in previous reports. [21] [22] [23] [24] A recent histopathologic study delineating 2 pathogenetic mechanisms of neuropathy has provided a hypothetical explanation: an ANCA-related vasculitis with fibrinoid necrosis of nerve vessels and a direct toxic effect on nerve fibres due to large numbers of extravascular eosinophilic infiltrates in ANCA-negative patients. 25 The patients with PNS involvement at baseline were older than those without, but we are unable to compare our findings with previous reports because data about the age of patients with neuropathy at disease onset are unavailable in larger cohorts of EGPA patients. 2, 4, 5, 17, [20] [21] [22] [23] Symptoms of neuropathy improved after corticosteroids and immunosuppressive drugs were administered, but patients were nevertheless left with chronic deficits. Neurological damage is important in these patients in view of its impact on long-term disability, function, and quality of life. The VDI score is limited because it does not evaluate severity or disability. The Combined Damage Assessment distinguishes between sensory and motor neuropathy and grades sensory neuropathy as mild, moderate, and severe, but it does not evaluate disability. 26 The Inflammatory Neuropathy Cause and Treatment ODSS, which is a part of Guy's Neurological Disability Scale, has been proposed as a preferential outcome measure in chronic inflammatory demyelinating polyneuropathy clinical trials. 27, 28 It has been shown to have good validity, reliability, and responsiveness; covers both upper and lower limbs dysfunction; has good clinimetric properties; and captures a high proportion of variances in disability. 9, 28, 29 Moreover, ODSS is simple to administer, is user-friendly, and requires only minimal training for physicians.
In our patients, ODSS was able to measure the degree of disability and improvement, related to both the severity of symptoms and the degree of neurological involvement.
A significant decrease in the ODSS was observed within 6 months of treatment, regardless of PNS involvement severity. Only a slow decreasing pattern was noted over a long-term period, suggesting the presence of a brief window of opportunity during which an adequate treatment could achieve a significant improvement of neurological deficits. Moreover, the fall in the ODSS score corresponded to the patients' self-reported perception of clinical and functional amelioration. It was not possible to demonstrate a correlation with a quality-of-life scale, such as the SF-36, mainly because of the retrospective design of the study. This assessment should be registered prospectively in subsequent study, for a better objective evaluation of the patient's quality of life and therapy efficacy. We arbitrarily decided to divide our cohort of patients into 2 groups, those with more severe PNS involvement and those with minor symptoms. Patients with severe symptoms, preventing all functions or daily activities almost in 1 limb, usually have an ODSS score of greater than 3; those with slighter symptoms preventing at least 1 but not all daily activities have an ODSS score of 3 or less. For this reason, a baseline cutoff of 3 was selected.
Patients with more severe neurological disease at baseline (ODSS >3) continued to have a higher ODSS score even at the last examination predicting a low therapeutic response.
Moreover, only patients with ODSS of greater than 3 presented neurological relapses during the follow-up compared with their counterparts with ODSS of 3 or less, despite standard immunosuppressive therapy and low doses of steroids to maintain disease remission. This suggests that the score is able to identify, at presentation, patients with higher risk of neurological worsening.
Finally, a significant correlation between the baseline ODSS score and the VDI score at the last examination was noted. Patients with a more severe neurological involvement at onset tend to have greater final damage due to both disease and therapies. This could further confirm the possible role of the disability score in early predicting the long-term outcome.
There are some limitations to our study. The low number of patients with PNS involvement is obviously linked to the monocentric format used to evaluate a rare disease. As a result, we were unable to observe differences in the score's efficacy in evaluating mononeuritis multiplex and polyneuropathy or the effects of different therapies. In addition, as the study was a retrospective and observational one, the attention was focused primarily on patients' clinical manifestations, nerve damage, and the role of ODSS to measure improvement mainly on the motor disability. Indeed, ODSS does not directly assess pain or paresthesias (only indirectly), despite the fact that these usually are a cardinal feature of the disease. Because the clinical examinations were not blinded, study results must be interpreted cautiously. Patients were treated uniformly, and the study was characterized by a consistent, scrupulous attention toward the patients over a long-term period. Finally, it must be considered that this tool is designed for quick rheumatologic outpatient assessment and cannot replace a complete neurological evaluation.
In conclusion, ODSS, an outcome measure proposed for chronic inflammatory demyelinating polyneuropathy clinical trials, seems to be a rapid, simple, efficient instrument to evaluate, also at presentation, the severity of patients' disability and nerve damage even in peripheral neuropathy due to vasculitis and to measure degree of disability and improvement over the course of time.
Nevertheless, there is a need to develop a specific score that could better take into account motor and sensory aspect of these manifestations. However, ODSS could be a useful tool to use now until the next-generation one will be developed.
Further studies in larger cohorts of patients are warranted to evaluate the pertinence of this score in patients affected with ANCA-associated vasculitis with peripheral neuropathy and possibly justify the use of more aggressive therapies, in accordance with the treat to target concept.
